BIO 2026: How NIH cuts have threatened US competitiveness against China
Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.
25 June 2026
25 June 2026
Investors at BIO 2026 say lost life sciences investment has left the US vulnerable while China fosters future big pharma competitors.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.